French vaccine maker Valneva said it would supply the UK with up to 190 million doses of its coronavirus vaccine candidate over a five-year period
said on Monday it would supply the UK with up to 190 million doses of its coronavirus vaccine candidate, VLA2001, over a five-year period.
Under the agreement, and if the vaccine development is complete, Valneva will initially provide the UK government with 60 million doses in the second half of 2021 at the cost of 470 million euros . The UK government can then opt for more than 40 million doses in 2022 and a further 30 million-90 million doses, in total, between 2023 and 2025.
Revenue from these options could amount to almost 900 million euros, Valneva said, adding that the UK is also investing up-front to ramp up and develop the vaccine, which is expected to have a two-dose regimen.will supply its CpG 1018 adjuvant to produce up to 100 million doses of Valneva's vaccine next year.
Valneva expects the vaccine candidate to enter clinical studies by the end of this year and potentially gain regulatory approval in the second half of 2021.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AstraZeneca Resumes Its COVID-19 Vaccine Trials In The U.K.The company had placed its worldwide vaccine trials on hold for several days. It now says a safety review by regulators and reviewers is complete. No word on when studies in the U.S. might resume.
Read more »
Pfizer, BioNTech propose expanding COVID-19 vaccine trial to 44,000 volunteersPfizer Inc and BioNTech SE have proposed to the U.S Food and Drug Administration (FDA) to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to about 44,000 participants, the companies said on Saturday.
Read more »
Pfizer, BioNTech propose expanding COVID-19 vaccine trial to 44,000 volunteersPfizer Inc and BioNTech SE on Saturday proposed to the U.S Food and Drug Administration (FDA) to expand their Phase 3 pivotal COVID-19 vaccine trial to about 44,000 participants while increasing the diversity of the trial population.
Read more »
When will there be a COVID-19 vaccine and should you trust that it's safe?Americans want a COVID-19 vaccine—but worry that it could be rushed out before the election. Here's what the science says.
Read more »
AstraZeneca resumes UK trials of COVID-19 vaccine halted by patient illnessAstraZeneca has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs, the company said on Saturday.
Read more »
AstraZeneca Covid-19 Vaccine Trials Resume in U.K.The company has ended a pause in clinical trials for its experimental coronavirus vaccine in the U.K. after regulators concluded it was safe to do so. The trials were halted globally after a person who received the vaccine had an unexplained illness.
Read more »